Suraksha Diagnostic Limited operates a chain of diagnostic centers in India. It offers pathology testing services, such as microbiology, serology, molecular biology, histopathology, cytopathology, clinical pathology, and haematology; genomics testing, including microarray, noninvasive prenatal, quantitative fluorescent polymerase chain reaction, fluorescence in situ hybridization, and karyotyping; and radiology testing that includes X ray, magnetic resonance imaging, computed tomography scan, USG, DEXA scan, OPG, and mammography. The company also provides Cardiology testing services comprises electrocardiogram, echocardiogram, stress test / treadmill test, wireless holter monitoring, colour doppler, peripheral doppler, and pulmonary function test; gastroenterology, such as upper and lower GI endoscopy, sigmoidoscopy, proctoscopy, colonoscopy, and proctosigmoidoscopy; and neurology testing services, including electroencephalogram, electromyography, and nerve conduction velocity test. In
| Current Price | ₹288.95 |
|---|---|
| Market Cap | ₹1,597 Cr |
| Sector | Health Care > Health Care Equipment and Services > Health Care Providers and Services |
| Sub-Industry | Health Care Services > Medical Diagnostic Centres |
| P/E Ratio | 48.2 |
| Return on Equity | 13.84% |
| 52-Week Range | ₹224.10 – ₹360.00 |
| Beta (1Y) | 0.56 |
| Dividend Yield | 0.17% |
| Revenue | ₹88 Cr |
|---|---|
| Net Profit | ₹13 Cr |
| EPS (Basic) | ₹2.50 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
1. Diagnostic Centres for Carrying out Various Pathology and Radiology Services-100%
SURAKSHA DIAGNOSTIC LIMITED is trading at ₹288.95, with a market capitalisation of ₹1,597 Cr.
SURAKSHA DIAGNOSTIC LIMITED operates in the Health Care > Health Care Equipment and Services > Health Care Providers and Services space (Health Care Services > Medical Diagnostic Centres).
SURAKSHA DIAGNOSTIC LIMITED has a P/E of 48.2 and a return on equity of 13.84%.
In Q1 FY27, SURAKSHA DIAGNOSTIC LIMITED reported revenue of ₹88 Cr and net profit of ₹13 Cr, with basic EPS of ₹2.5 (consolidated, parsed from the company's exchange filing).